Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05154201
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China
Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04643769
- Locations
- 🇺🇸
St. Francis Sleep, Allergy & Lung Institute, Clearwater, Florida, United States
🇺🇸Mayo Clinic Hospital, Jacksonville, Florida, United States
🇺🇸Avanza Medical Research, Pensacola, Florida, United States
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
- Conditions
- Advanced Solid TumorMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03950570
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA Health Burbank Specialty Care, Burbank, California, United States